Sawai Group Holdings Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 9 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/10 | ¥44.16 | ¥21.04 | -52.4% |
| 2026/05/14 | ¥25.64 | ¥-2.70 | -110.5% |
| 2026/02/12 | ¥59.88 | ¥42.46 | -29.1% |
| 2025/11/13 | ¥35.10 | ¥8.27 | -76.4% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
2.8M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
1.5M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
1.0M | +6.16% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
772.0K | +0.43% | |
|
Advisors Series Trust-Pzena International Small Cap Value Fund
|
500.7K | 0.00% | |
|
Matthews International Funds-Matthews Asia Dividend Fund
|
388.8K | 0.00% |
Dividend History 3Years Growth
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥56 | +3.7% |
| 2025 | ¥54 | +13.3% |
| 2024 | ¥48 | +10.0% |
| 2023 | ¥43 | 0.0% |
| 2022 | ¥43 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥193,816M | ¥163,702M | ¥176,862M | ¥189,024M |
| Gross Profit | ¥66,652M | ¥50,252M | ¥54,319M | ¥56,352M |
| Operating Income | -¥35,888M | ¥16,054M | ¥18,619M | ¥20,808M |
| Pretax Income | -¥35,743M | ¥16,248M | ¥18,820M | ¥20,958M |
| Net Income | -¥28,269M | ¥12,667M | ¥13,695M | ¥22,938M |
| EPS | -¥215.18 | ¥96.20 | ¥103.93 | ¥184.45 |
| Operating Margin | -18.52% | 9.81% | 10.53% | 11.01% |
| Balance Sheet | ||||
| Total Assets | ¥349,502M | ¥364,165M | ¥382,024M | ¥354,623M |
| Total Equity | ¥190,067M | ¥201,643M | ¥212,662M | ¥173,854M |
| Total Liabilities | ¥159,435M | ¥162,522M | ¥169,362M | ¥180,769M |
| Cash | ¥47,717M | ¥33,076M | ¥26,368M | ¥38,785M |
| Interest-bearing Debt | ¥66,749M | ¥73,132M | ¥82,890M | ¥91,339M |
| Equity Ratio | 54.38% | 55.37% | 55.67% | 49.03% |
| D/E Ratio | 0.35 | 0.36 | 0.39 | 0.53 |
| Cash Flow | ||||
| Operating CF | ¥34,310M | ¥13,026M | ¥23,149M | ¥27,851M |
| Investing CF | -¥30,395M | -¥27,134M | -¥23,112M | ¥6,480M |
| Financing CF | -¥11,262M | -¥1,267M | ¥2,363M | -¥32,704M |
| Free CF | ¥10,966M | -¥14,115M | -¥1,500M | ¥337M |
| Efficiency | ||||
| ROE | -14.87% | 6.28% | 6.44% | 13.19% |
| ROA | -8.09% | 3.48% | 3.58% | 6.47% |
Latest IR Information
-
Saway Group Holdings Co., Ltd. 2027 Fiscal Year Q1 Consolidated Financial Results Summary
For the first quarter of the 2027 fiscal year, consolidated net sales were 51,622 million yen (YoY +4.3%), operating income was 4,953 million yen (△29.0% YoY), and net income attributable to owners of the parent was 2,429 million yen (△50.3%...
Read more -
(Correction) Notice regarding Stock Split (Simple Absorption-type Merger)
This document corrects the notice on the stock split disclosed on June 25, 2026, explicitly detailing the corrected portion related to the treatment of stock acquisition rights. The company has not issued stock acquisition rights attached to bonds, and the...
Read more -
Completion of New Share Payment for Restricted Stock Compensation ｜ July 24, 2026
Sawai Group Holdings announced that it has completed the payment process for 30,789 new shares issued as restricted stock compensation on July 24, 2026.
Read more -
【Sawai Group Holdings】Notice of Business Reorganization and Stock Split｜June 2026
Sawai Group Holdings will implement a company split effective September 1, 2026, to transfer the non-alcoholic fatty liver disease treatment app business to a wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd., aiming to improve business efficiency and corporate value.
Read more -
[Sawai Group HD] New Share Issuance of Restricted Stock Compensation | July 2026
Sawai Group Holdings will issue 30,789 new shares of common stock on July 24, 2026, introducing a restricted stock compensation plan. The purpose is to promote mid- to long-term improvements in corporate value and align executives' performance.
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,171
Rating Score: 2.00 (Based on 9 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the manufacture and sale of pharmaceuticals. The company offers generic drugs in various dosage forms for therapeutic areas comprising cardiovascular and antibiotic preparations, central nervous system drugs, other metabolic drugs, digestive tract medicines, blood and body fluid medications, allergy medications, respiratory medicine, vitamin supplements, oncology drugs, chemotherapeutic agents, genitourinary and anal drugs, and others. It sells its generic drugs through distributors, wholesalers, and retailers. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
